Purpose: The quantitative assessment of Positron Emission Tomography (PET) scans using standardized uptake value and derived parameters proved to be superior to traditional qualitative assessment in several retrospective or mono-centric prospective reports. Since different scanners give different quantitative readings, a program for clinical trial qualification (CTQ) is mandatory to guarantee a reliable and reproducible use of quantitative PET in prospective multi-centre clinical trials and in every-day clinical life. Methods: We set up, under the auspices of Italian Foundation on Lymphoma (FIL), a CTQ program consisting of the PET/CT scan acquisition and analysis of 18F and 68Ge NEMA/IEC image quality phantoms for the reduction of inter-scanner variability. Variability was estimated on background activity concentration (BAC) and sphere to background ratio (SBR). Results: The use of a 68Ge phantom allowed reducing the inter-scanner variability among different scanners from 74.0% to 20.5% in BAC and from 63.3% to 17.4% in SBR compared to using the 18F phantom. The CTQ criteria were fulfilled at first round in 100% and 28% of PET scanners with 68Ge and 18F respectively. Conclusions: The 68Ge phantom proved a reliable tool for PET scanner qualification, able to significantly reduce the potential sources of error while increasing the reproducibility of PET derived quantitative parameter measurement.

Chauvie, S., Bergesio, F., Fioroni, F., Brambilla, M., Biggi, A., Versari, A., et al. (2016). The 68Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian Foundation on Lymphoma). PHYSICA MEDICA, 32(5), 651-656 [10.1016/j.ejmp.2016.04.004].

The 68Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian Foundation on Lymphoma)

Guerra L.;
2016

Abstract

Purpose: The quantitative assessment of Positron Emission Tomography (PET) scans using standardized uptake value and derived parameters proved to be superior to traditional qualitative assessment in several retrospective or mono-centric prospective reports. Since different scanners give different quantitative readings, a program for clinical trial qualification (CTQ) is mandatory to guarantee a reliable and reproducible use of quantitative PET in prospective multi-centre clinical trials and in every-day clinical life. Methods: We set up, under the auspices of Italian Foundation on Lymphoma (FIL), a CTQ program consisting of the PET/CT scan acquisition and analysis of 18F and 68Ge NEMA/IEC image quality phantoms for the reduction of inter-scanner variability. Variability was estimated on background activity concentration (BAC) and sphere to background ratio (SBR). Results: The use of a 68Ge phantom allowed reducing the inter-scanner variability among different scanners from 74.0% to 20.5% in BAC and from 63.3% to 17.4% in SBR compared to using the 18F phantom. The CTQ criteria were fulfilled at first round in 100% and 28% of PET scanners with 68Ge and 18F respectively. Conclusions: The 68Ge phantom proved a reliable tool for PET scanner qualification, able to significantly reduce the potential sources of error while increasing the reproducibility of PET derived quantitative parameter measurement.
Articolo in rivista - Articolo scientifico
Clinical trials; Lymphoma; Positron emission tomography; Quantitative imaging;
Clinical trials; Lymphoma; Positron emission tomography; Quantitative imaging; Calibration; Clinical Trials as Topic; Equipment Design; Fluorodeoxyglucose F18; Germanium; Humans; Image Processing, Computer-Assisted; Lymphoma; Multicenter Studies as Topic; Patient Selection; Positron Emission Tomography Computed Tomography; Radioisotopes; Reproducibility of Results; Retrospective Studies; Phantoms, Imaging; Positron-Emission Tomography
English
2016
32
5
651
656
none
Chauvie, S., Bergesio, F., Fioroni, F., Brambilla, M., Biggi, A., Versari, A., et al. (2016). The 68Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian Foundation on Lymphoma). PHYSICA MEDICA, 32(5), 651-656 [10.1016/j.ejmp.2016.04.004].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/240814
Citazioni
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 17
Social impact